SCHEMBL22940435

SCHEMBL22940435

Cc1cccc(-c2cc3ccccc3[nH]2)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.59
AURKB Q96GD4 1/20 0.59
GSK3B P49841 1/20 0.54
ESR1 P03372 2/20 0.53
RAB9A P51151 4/20 0.50
NPC1 O15118 3/20 0.50
CCR1 P32246 1/20 0.50
CCR8 P51685 1/20 0.50
KDM4E B2RXH2 4/20 0.46
MAPT P10636 4/20 0.46
MEN1 O00255 3/20 0.46
ALDH1A1 P00352 3/20 0.46
HPGD P15428 3/20 0.46
KMT2A Q03164 3/20 0.46
USP2 O75604 1/20 0.46
LMNA P02545 1/20 0.46
POLB P06746 1/20 0.46
GAA P10253 1/20 0.46
ALOX15 P16050 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23641151 0.87 GSK3B (0.62) AURKAAURKBGSK3BESR1RAB9A
SCHEMBL13831039 0.87 AURKA (0.50) AURKAAURKBGSK3BESR1RAB9A
SCHEMBL695383 0.81 CCR1 (0.44) AURKAAURKBGSK3BESR1RAB9A
SCHEMBL14838833 0.81 CYP1A1 (0.49) AURKAAURKBCCR1CCR8KDM4E
SCHEMBL12090863 0.80 CTSV (0.56) RAB9ANPC1KDM4EMAPTMEN1
SCHEMBL20987231 0.79 RAB9A (0.65) AURKAAURKBGSK3BESR1RAB9A
SCHEMBL11895098 0.79 GSK3B (0.62) AURKAAURKBGSK3BESR1RAB9A
Hydrochloric Acid SCHEMBL11364351 0.76 KDM4E (0.65) RAB9ANPC1CCR1CCR8KDM4E
SCHEMBL23389649 0.76 RIPK1 (0.52) CCR1CCR8
SCHEMBL29796712 0.76 RIPK1 (0.52) CCR1CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584745-B2 Aromatic heterocyclic compound, intermediate thereof, preparation method therefor, and pharmaceutical composition and use thereof SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) 2023-02-21 US disclosed
US-20210032241-A1 AROMATIC HETEROCYCLIC COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) 2021-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210032241-A1 AROMATIC HETEROCYCLIC COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF ALK, NOTUM, WEE1 AURKA 1843/4885AURKB 1939/4885GSK3B 1080/4885
US-11584745-B2 Aromatic heterocyclic compound, intermediate thereof, preparation method therefor, and pharmaceutical composition and use thereof ALK, NOTUM, WEE1 AURKA 1843/4885AURKB 1939/4885GSK3B 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.